Arfolitixorin’s potential
in other cancer types

Chemotherapy is a central component in the treatment of several types of cancer, and arfolitixorin could enhance the efficacy of chemotherapy in a vast number of patient populations. This opens opportunities to broaden the clinical application of arfolitixorin and thereby potentially increase its commercial value over time.

Drug combinations with 5-FU-based chemotherapy are used not only for colorectal cancer but also for the treatment of pancreatic, gastric, breast, and head and neck cancers, among others. One common trait shared by colorectal cancer and pancreatic cancer is that the cancer cells have a high mutation rate, which means they frequently alter their properties and become difficult to treat and resistant even to modern immunotherapies.

Gastric cancer is a very common form of cancer in Asian populations, but also occurs in Europe, where chemotherapy combined with leucovorin, one of the most common folate drugs, is an established standard in both first-line and later lines of treatment. In lung and breast cancer, treatment strategies also largely target thymidylate synthase (TS), a key enzyme that regulates cell growth. This further underscores the potential of arfolitixorin, provided that clinical studies can demonstrate superior efficacy compared to current standard therapies. To obtain approval for these new indications, additional clinical trials will likely be required.

Arfolitixorin has significant potential to contribute with something unique: a product that, once approved for marketing, can be integrated into globally established treatment regimens for some of the world’s most common forms of cancerWith patent protection until the 2040s and blockbuster potential exceeding SEK 10 billion, the foundation is in place for both scientific and commercial success.